Ind-Swift group, a Chandigarh-based research-driven pharmaceutical group with presence across 45 countries, expects to close the current fiscal with collective sales of Rs 1,200 crore from its two firms – Ind-Swift Limited and Ind-Swift Laboratories.
The group is expecting a net profit of about Rs 74 crore in the current fiscal from the two companies, besides anticipating a 25 per cent growth in sales during the next financial year.
“In the current fiscal, we are expecting the two firms to have collective sales of Rs 1,200 crore,” Ind Swift Limited chairman, Gopal Munjal, told Business Standard.
According to Ind-Swift vice-president (finance) Amit Tarfdar, while the group is expecting Ind-Swift Limited to clock revenues of Rs 600 crore, Ind-Swift Laboratories' revenue is likely touch Rs 590 crore. “We are expecting a net profit of Rs 34-35 crore and Rs 38-39 crore from these two companies respectively this financial year,” he said.
